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Fig. 1 
The specific binding of TAK-615 (A), SAR-100842 (B) and BMS-896202 (C) to membranes 
expressing the human LPA1 receptor.  Compounds were incubated with either parental 
membranes or membranes expressing the LPA1 receptor.  The binding signal was expressed as 
the phase shift in the interference fringe patterns measured in milliradians.  The data from the 
parental membrane fractions was subtracted from the LPA1 receptor expressing fractions point 
by point to obtain the specific binding interaction of the compounds with the LPA1 receptor.  
Data points are derived from at least three separate experiments and plotted as means with 
S.E.M..  Compound affinity was calculated using a comparison fit of a one or two site binding 
model. 
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Fig. 2 
Representative graphs to demonstrate the different inhibitory functional profiles of TAK-615 
(▲), SAR-100842 (■) & BMS-986202 (●) in a range of LPA driven functional assays using 
recombinant cell lines expressing the human LPA1 receptor.  In all cases a four-parameter curve 
fit algorithm was used to define compound potency.  (A) Calcium mobilisation assay.  Data 
points are derived from at least quadruplicate wells with S.E.M..  BMS-986202 showed full 
inhibition, SAR-100842 showed weak inhibition and TAK-615 showed partial inhibition.  (B) 
cAMP accumulation assay.  Data points are from duplicate wells.  TAK-615 showed no 
inhibition, SAR-100842 & BMS-986202 showed full inhibition.  (C) Millipore GTPγS assay.  
Data is derived from duplicate wells.  SAR-100842 & BMS-986202 showed full inhibition.  
TAK-615 showed no inhibition.  (D) DiscoverX PathHunter β-arrestin2 assay. TAK-615 gave 
partial inhibition.  SAR-100842 & BMS-986202 showed full inhibition. 
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Fig. 3 
Representative data comparing the ability of TAK-615, SAR-100842 and BMS-986202 to inhibit 
10 µM LPA stimulated RhoA activation in MeT-5A cells.  Data points are derived from 
quadruplicate wells with S.E.M..  Data was analysed using a one-way ANOVA with a Dunnett’s 
multiple comparisons test. ≈ P< 0.001 LPA vs Vehicle.  * P< 0.05, ** P< 0.01, *** P<0.001 
compound vs LPA. 
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Fig. 4 
LPA increases the apparent affinity of TAK-615, shifts SAR-100842 binding to a single high 
affinity site but blocks binding of BMS-986202 to the LPA1 receptor.  Parental membranes or 
membranes expressing the LPA1 receptor were incubated with a single concentration of LPA 
(10µM) for 30 mins before addition of TAK-615 (A), SAR-100842 (B) or BMS-986202 (C).  
The binding signal was expressed as the phase shift in the interference fringe patterns measured 
in milliradians.  The data from the parental membrane fractions was subtracted from the LPA1 
receptor expressing fractions point by point to obtain the specific binding interaction of the 
compounds with the LPA1 receptor in the presence or absence of LPA.  Data points are derived 
from at least three separate experiments and plotted as means with S.E.M..  Compound affinity 
was calculated using a comparison fit of a one or two site binding model. 
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Fig. 5 
Pre-incubating membranes expressing the LPA1 receptor with SAR-100842 prevents binding of 
BMS-986202.  Parental membranes or membranes expressing the LPA1 receptor were pre-
incubated for 30 mins with 10 µM of a compound before titration with TAK-615 (A), SAR-
100842 (B) or BMS-986202 (C).  The binding signal was expressed as the phase shift in the 
interference fringe patterns measured in milliradians.  The data from the parental membrane 
fractions was subtracted from the LPA1 receptor expressing fractions point by point to obtain the 
specific binding interaction of the compounds with the LPA1 receptor in the presence of another 
compound.  Data points are derived from at least three separate experiments and plotted as 
means with S.E.M..  Compound affinity was calculated using a best fit one or two-site binding 
model. (A) TAK-615 binding is best described by a one-site model in the presence of SAR-
100842 and BMS-986202.  (C)  TAK-615 decreased the apparent affinity of BMS-986202.  
SAR-100842 oblates BMS-986202 binding but (B) BMS-986202 has no effect upon SAR-
100842 binding.  The binding of SAR-100842 in the presence of TAK-615 best fits a one-site 
model. 
 
 
